psychedelic drug

Arrows hitting targets
Biotech

Gilgamesh links psychedelic to 94% remission rate in depression

The phase 2a data further the biotech’s attempt to follow the trail blazed by Johnson & Johnson.
Nick Paul Taylor May 27, 2025 11:00am
magic mushroom

Relmada reconsiders plans to test psilocybin for obesity

Mar 28, 2025 10:00am
Close up of hallucinogenic mushrooms

Cybin psychedelic reduces depression severity after 12 months

Nov 18, 2024 12:57pm
compass map direction find trail north

Compass delays phase 3 psychedelic data, lays off 30% of staff

Oct 31, 2024 9:00am
Withdraw cancel rip up application

Psyence walks away from acquisition of fellow psilocybin biotech

Oct 7, 2024 5:16am
magic mushroom

Psyence acquires fellow psilocybin biotech Clairvoyant

Sep 6, 2024 9:25am